Q-omics provides the consensus-scored ISCU profile across patient tissues and cancer cell-line models. ISCU expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, ISCU is differentially expressed in 10, with the highest sampling consensus in LIHC. Additionally, ISCU protein abundance shows 30,857 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UCS, LIHC, and GBM as cancer lineages where ISCU shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ISCU — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ISCU survival associations across molecular data types. ISCU RNA expression shows survival associations in the most cancer types (29), followed by mutation status (3) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ISCU RNA expression–survival associations across cancer types. High ISCU expression shows unfavorable associations in UVM, but favorable associations in UCS, CESC, KIRP, ACC and PAAD. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UCS as the clearest survival context for ISCU RNA expression.
This table summarizes ISCU tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 9. The strongest signals are observed in LUSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ISCU. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ISCU shows lower tumor expression in LUSC, BLCA, LUAD and KIRC and higher tumor expression in LIHC and THCA. The LIHC box plot shows higher ISCU RNA expression in tumor versus normal tissue (log2 FC = +0.757, t-test p < 0.001).
This table shows molecular features associated with ISCU in patient tissues and cancer cell lines. In patient samples, ISCU shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ISCU RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Lymphoma.
